BioE3 Policy: Biotechnology For Economy, Environment And Employment

Introduction

Biotechnology has quietly become one of India’s most consequential growth sectors, yet for years it lacked a single, unifying national framework. The BioE3 Policy, Biotechnology for Economy, Environment and Employment, was designed to fill that gap.

The Union Cabinet, led by Prime Minister Narendra Modi, approved the policy on 24 August 2024, building a framework that brings together biotechnology, engineering and digitalisation to build a more equitable and sustainable future through biomanufacturing. It is positioned as India’s first dedicated national biotechnology policy, and its ambitions are stated in unusually direct terms: to make India a global hub for high-performance biomanufacturing by 2047.

Background

India’s bioeconomy has grown at a pace few sectors can match, a compounding rise rather than a steady one. It expanded roughly sixteen-fold from $10 billion in 2014 to $165.7 billion in 2024, contributing around 4.25% to national GDP and growing at a compound annual rate of nearly 18% over the preceding four years. By mid-2026, government figures placed the sector even higher, at more than $190 billion, moving toward the stated target of $300 billion by 2030. Startups multiplied alongside this growth, often faster than the regulatory and financing structures around them: the number of bioeconomy companies rose from 5,365 in 2021 to 10,075 by 2024, and more recent estimates put the figure past 11,800.

Despite this expansion, the ecosystem before BioE3 remained fragmented, spread across separate agricultural, pharmaceutical and industrial biotech efforts with no common architecture for scale-up, regulation or funding, growth, in effect, outpacing the coordination needed to sustain it. The policy was conceived to unite these strands under one strategic umbrella, aligned with India’s broader Net Zero and Viksit Bharat @2047 goals.

Figure 1: India’s Bioeconomy Growth, 2014–2030 (USD Billion)

Source: Press Information Bureau, Government of India.

Functioning

The policy focuses on six thematic sectors: bio-based chemicals and enzymes, functional foods and smart proteins, precision biotherapeutics, climate-resilient agriculture, carbon capture and utilisation, and futuristic marine and space research. Its core delivery mechanism rests on building physical and institutional infrastructure, establishing Biomanufacturing and Bio-AI hubs and Biofoundries that will accelerate technology development and commercialisation, while prioritising ethical biosafety and global regulatory alignment to strengthen India’s competitiveness.

Figure 2: Salient Features of the BioE3 Policy

Source: Press Information Bureau (PIB), Government of India. 

A distinctive feature is the emphasis on decentralised growth. The policy aims to generate employment particularly in tier-II and tier-III cities by setting up biomanufacturing hubs that draw on local biomass, encouraging regional economic development. On the technology side, a national network, comprising Bio-AI Hubs, biofoundries and biomanufacturing centres, has been set up to support the rollout, and a Memorandum of Understanding between the Department of Biotechnology and MeitY was signed in August 2025 to build an AI-driven biological research ecosystem, with MeitY providing compute and data infrastructure and DBT contributing biological datasets.

Implementation has moved through structured calls for proposals. The first DBT–BIRAC joint call for Bio-AI hub proposals, issued in April 2025, received 284 letters of intent, of which 16 were shortlisted for further support after a four-stage evaluation process; a rolling call opened in November 2025 continues to admit proposals on an ongoing basis.

Table 1: Key Thematic and Institutional Pillars of BioE3

Source: Press Information Bureau, Government of India, 2024.

Performance

Early indicators suggest the policy is translating into measurable activity rather than remaining a paper framework. Nearly 40% of selected proposals under the Bio-AI call are being led by startups and private industry through public-private partnership models, while academic institutions have taken the lead in agri-biotech applications. On workforce development, a proposal to introduce 100 post-doctoral fellowships for Indian scientists working abroad is under review, aimed at reversing brain drain.

The wider bioeconomy that BioE3 sits within shows sustained momentum. The sector recorded 17-18% annual growth in the past year, rising from roughly $165 billion to $195 billion, with the India Bioeconomy Report 2026 noting the sector now contributes nearly 5% to GDP and has more than doubled since 2020. The same report counted over 11,800 biotech startups currently active. Supporting infrastructure has scaled too: BIRAC has set up 95 bio-incubation centres nationwide since its founding in 2012.

However, growth remains geographically skewed. Five states — Maharashtra, Karnataka, Telangana, Gujarat and Andhra Pradesh, account for more than two-thirds of bioeconomy value, while the entire eastern and north-eastern belt contributes under 6%, a disparity BioE3’s tier-II/III hub strategy is explicitly meant to address but has not yet visibly closed.

Table 2: Bioeconomy Progress Indicators

Source: DD News; Press Information Bureau, Government of India.

Emerging Issues

Several structural gaps could limit BioE3’s reach. The most persistent is regional concentration, bio-manufacturing capacity remains clustered in a handful of southern and western states, leaving north-east and eastern India as a policy blind spot despite the stated intent to decentralise.

Regulatory friction is another concern; delays in approvals for genetically modified crops continue to slow agricultural biotech despite demonstrated productivity gains elsewhere in the world. Such uncertainty has a ripple effect, deterring investors who price in regulatory risk, discouraging firms from committing to commercial-scale facilities, and slowing downstream adoption by industries unsure of a product’s regulatory status.

Financing is a third constraint. Compared to IT and conventional pharma, the bioeconomy attracts comparatively thin venture capital and foreign direct investment, and early-stage biomanufacturing, which requires capital-intensive pilot and scale-up facilities, is particularly underfunded relative to lab-stage research.

Finally, workforce depth remains an issue: bioinformatics, fermentation technology and biotech-specific intellectual property expertise are all in short supply relative to the pace of hub creation the policy envisages. Stronger industry-academia collaboration and more targeted skill development would help close this gap and keep talent supply aligned with the policy’s long-term goals.

Way Forward & Suggestions

Closing the regional gap requires biofoundry and Bio-AI hub allocations to be weighted deliberately toward under-represented states rather than following existing industrial clusters. Regulatory streamlining, particularly around GM crop approvals and the Biological Research Regulatory Approval Portal (BioRRAP), needs to move from single-window intent to single-window practice, with published turnaround-time targets. On financing, the recently announced Research, Development and Innovation Fund should be explicitly tranche-allocated toward pilot-scale and commercial-scale biomanufacturing facilities, not only early research, since that is where India’s biotech pipeline currently leaks value to foreign contract manufacturers.

To coordinate these efforts, a National Bioeconomy Mission, proposed in earlier sectoral reports but not yet operationalised, should be constituted to bring the Department of Biotechnology, MeitY, state industry departments and BIRAC under one implementation framework, closing the inter-agency gaps that slow hub rollout. A publicly tracked BioE3 dashboard, reporting hub-wise investment, startup absorption and state-wise employment generation, would bring the transparency the policy currently lacks. And given the tier-II/III city ambition, a dedicated skilling partnership with state technical universities should be built into every new biofoundry from the design stage, rather than added after the facility becomes operational.

Conclusion

BioE3 arrives at a moment when India’s underlying bioeconomy is already growing faster than most global peers, which gives the policy a genuine tailwind rather than a standing start. Its institutional architecture, Bio-AI hubs, biofoundries, a formal MeitY partnership is more concrete than many comparable sectoral visions at this stage.

The open questions are familiar ones: whether hub investment actually reaches the states it is meant to develop, whether regulatory clearance keeps pace with proposal volume, and whether financing follows research out of the laboratory and into commercial-scale production. On present evidence, the policy has moved credibly from announcement to implementation. Whether it closes India’s regional and capital gaps by 2030 will determine how much of its 2047 ambition is realised.

References

1. Prime Minister’s Office, Government of India. (2024, August 24). Cabinet approves BioE3 (Biotechnology for Economy, Environment and Employment) policy for fostering high performance biomanufacturing. PM India. https://www.pmindia.gov.in/en/news_updates/cabinet-approves-bioe3-biotechnology-for-economy-environment-and-employment-policy-for-fostering-high-performance-biomanufacturing/
2. Press Information Bureau, Government of India. (2024, August 31). S&T Minister Dr. Jitendra Singh formally releases new BioE3 policy, hails India as global torch bearer of next industrial revolution. Press Information Bureau. https://www.pib.gov.in/PressReleaseIframePage.aspx?PRID=2050446&lang=2&reg=3
3. Department of Biotechnology, Government of India. (2024). Cabinet approves BioE3 (Biotechnology for Economy, Environment and Employment) policy for fostering high performance biomanufacturing. Department of Biotechnology. https://dbtindia.gov.in/latest-announcement/cabinet-approves-bioe3-biotechnology-economy-environment-and-employment-policy
4. Press Information Bureau, Government of India. (2025, February 7). Union Minister Dr. Jitendra Singh called on states to establish BioE3 cells as part of India’s biotechnology revolution and realize Bio-Vision in Viksit Bharat by 2047. Press Information Bureau. https://www.pib.gov.in/PressReleasePage.aspx?PRID=2100800

About the Contributor

Paridhi Passi is a Research and Editorial Intern at IMPRI and a Political Science (Hons.) student at Daulat Ram College, University of Delhi. Her academic interests lie in public policy and governance.

Acknowledgement 

The author sincerely thanks Pallavi Lad and Sneha Sharma for reviewing this article as well as the IMPRI team for their constructive comments and editorial guidance during the review of this policy update.

Disclaimer: All views expressed in the article belong solely to the author and not necessarily to the organisation.

Read More at IMPRI:

Accessible India Campaign (Sugamya Bharat Abhiyan) 2015 : An Analysis of Progress and Challenges

Seniorcare Ageing Growth Engine (SAGE) Initiative (2021) : Harnessing Innovation for India’s Ageing Population